Oppenheimer cuts Abbott stock price target to $115 on guidance By Investing.com

Abbott reported Q1 2026 revenue of $11.16 billion, topping the $11.00 billion consensus, but GAAP EPS of $0.61 missed expectations of $0.86 and Oppenheimer’s $0.90 estimate. The firm cut its price target to $115 from $132 while keeping an Outperform rating, and Abbott also lowered FY2026 adjusted EPS guidance to $5.38-$5.58 from $5.55-$5.80, including $0.20 dilution from the Exact Sciences acquisition. Shares trade near $95.47, down 23% YTD and close to the 52-week low.

Analysis

The market is treating this as a benign reset, but the more important signal is that ABT’s multiple is now being asked to absorb a near-term earnings gap while the top line is still intact. When a defensive healthcare compounder cuts visible earnings expectations without breaking revenue, the stock usually trades less on fundamentals than on the market’s confidence in margin repair; that makes the next 1-2 quarters about delivery rather than absolute growth. The risk is that investors anchor to the high-level guidance band and miss that the market may not re-rate until the path to incremental EBIT expansion is clearer.

The Exact Sciences contribution is the key second-order issue. Near-term dilution plus integration noise can mask the fact that the acquisition gives ABT a more data-rich diagnostics footprint and a larger cross-sell surface, but only if management can avoid a prolonged period of stranded costs and subscale commercialization spend. If launch scaling in electrophysiology and structural heart lands in the back half of the year, the stock can re-rate quickly; if it slips, ABT becomes a classic “looks cheap but keeps getting cheaper” defensive trap.

The broader winner/loser dynamic is that the pressure shifts from category leaders with clean operating leverage toward smaller med-tech peers that depend on hospital capex cycles and physician adoption. ABT’s relative resilience also implies that suppliers and adjacent device names with exposure to the same end markets may see broader multiple compression if investors start demanding cleaner guidance execution. The contrarian take: the stock may already be discounting too much bad news, because consensus is still underappreciating how quickly a few points of margin recovery can compound in a company with this scale and dividend support.

Near term, the catalyst path is asymmetric: one clean quarter of margin stabilization can matter more than another modest revenue beat. The main tail risk is that pro forma reporting and acquisition accounting keep obscuring organic progress, which can delay institutional re-entry for months even if fundamentals improve underneath.

Key Decisions for Investors

• Go long ABT on weakness with a 3-6 month horizon; use the current compression in expectations to buy before back-half execution visibility improves. Best risk/reward if management can show even modest EBIT margin recovery and no further guide-downs.
• For tactically bullish exposure, buy ABT Jan-2027 calls or call spreads financed by selling near-term upside; the thesis is delayed re-rating rather than immediate momentum, so options should be structured for 2-4 quarter payoff.
• Pair long ABT / short IHI for 1-2 quarters if you want to isolate company-specific margin repair against a still-expensive med-tech basket; this works best if the market keeps rewarding cleaner guidance over headline growth.
• Avoid chasing EXAS on the print unless you have high conviction in integration; the setup is now about proving that incremental revenue translates into durable earnings, not just adding scale.
• If ABT fails to stabilize by the next quarterly update, cut quickly rather than averaging down; this is a multiple-support trade, and the downside accelerates if investors conclude the guide reset was still too optimistic.